A1CLJ

17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one

Created:2025-08-01
Last modified:  2026-03-04

Find related ligands:

Chemical Details

Formal Charge0
Atom Count48
Chiral Atom Count4
Bond Count53
Aromatic Bond Count6
2D diagram of A1CLJ

Chemical Component Summary

Name17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one
Systematic Name (OpenEye OEToolkits)(4~{R},4~{a}~{S},7~{a}~{R},12~{b}~{S})-3-(cyclopropylmethyl)-4~{a},9-bis(oxidanyl)-2,4,5,6,7~{a},13-hexahydro-1~{H}-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
FormulaC20 H23 N O4
Molecular Weight341.401
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs14.52O=C1CCC2(O)C3Cc4ccc(O)c5OC1C2(CCN3CC1CC1)c54
SMILESCACTVS3.385Oc1ccc2C[CH]3N(CC[C]45[CH](Oc1c24)C(=O)CC[C]35O)CC6CC6
SMILESOpenEye OEToolkits3.1.0.0c1cc(c2c3c1CC4C5(C3(CCN4CC6CC6)C(O2)C(=O)CC5)O)O
Canonical SMILESCACTVS3.385 Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6
Canonical SMILESOpenEye OEToolkits3.1.0.0 c1cc(c2c3c1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O
InChIInChI1.06 InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
InChIKeyInChI1.06 DQCKKXVULJGBQN-XFWGSAIBSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB00704 
NameNaltrexone
Groups
  • investigational
  • vet_approved
  • approved
DescriptionDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Synonyms
  • 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
  • N-Cyclopropylmethylnoroxymorphone
  • Naltrexone hydrochloride
  • Naltrexonum
  • N-Cyclopropylmethyl-14-hydroxydihydromorphinone
Brand Names
  • Apo-naltrexone
  • Contrave
  • Naltrexone
  • Embeda
  • Rpc-naltrexone
IndicationUsed as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Categories
  • Agents Causing Muscle Toxicity
  • Alcohol Deterrents
  • Alimentary Tract and Metabolism
  • Alkaloids
  • Analgesics
ATC-Code
  • N02AA56
  • N07BB04
  • A08AA62
CAS number16590-41-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Mu-type opioid receptorMDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRT...unknownantagonist
Kappa-type opioid receptorMDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLE...unknownantagonist
Delta-type opioid receptorMEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAI...unknownantagonist
Sigma non-opioid intracellular receptor 1MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYA...unknownantagonist
UDP-glucuronosyltransferase 1A1MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682